author-photo

Jason Jerome Lukas

University of California, San Francisco

4

Papers

9

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)